Skip to main content
Contact Us
Sign Up
Subscriber Sign In
navigation
サイト内検索
COVID-19
COVID-19 Update
Evaluate Vantage COVID-19 Report
COVID-19 Stories from Evaluate Vantage
Evaluate’s Business Continuity Plan
What We Do
Commercial Intelligence
Products
Evaluate Pharma
Evaluate Omnium
Evaluate Epi
Japan Drug Forecasts
Europe Drug Forecasts
Evaluate Custom Solutions
Evaluate Vantage
News
Analysis
Policy & Pricing
Data Insights
Events
Medtech
Therapy Areas
Editorial Team
About Evaluate Vantage
Evaluate for Biotech
How We Can Help You
Pharma and Biotech
Medtech
Financial Services
Management Consultancies
Service Providers
Customer Testimonials
Thought Leadership
About Us
Press Releases
Media Coverage
Executive Team
Vision & History
Careers
Current Vacancies
Contact Us
Sign Up for Evaluate Vantage
Subscriber Sign In
Search
Open configuration options
Search
Vantage
Covid-19
Covid-19 Coverage
Evaluate Vantage COVID-19 Report
News
Snippets
Deals
Trial results
Patents and litigation
Corporate strategy
Analysis
Interviews
Spotlight
Vantage points
Vantage views
Data Insights
M&A
IPO
NME approvals
Quarterly shareprice performance
Venture financing
Vantage data points
Other data
Events
Company events
Conferences
Upcoming events
Medtech
Therapy Areas
About
Editorial team
Sirtex Medical
July 03, 2019
Varian finally gets some beads as Boston does a swap
June 15, 2018
Snippet roundup: Panel says no to BTG and Sirtex says no to Varian
May 11, 2018
Snippet roundup: Pivotal fluffs from Faron and Fasenra
January 30, 2018
Varian goes internal with $1.6bn Sirtex deal
May 19, 2017
Snippet roundup: Bladder cancer nod for Keytruda and success for Syndax in melanoma
April 25, 2017
Sirtex trial miss means beads could stay as back-up
January 09, 2017
A quiet year for mid-size medtech
July 06, 2016
Smaller medtechs in charge of their own destiny
June 01, 2015
Asco – Sirtex spins surrogate hit but no chance for first-line use
March 17, 2015
Sirtex slips on its beads after trial miss
January 15, 2015
Mid-cap medtech shares rise in 2014 on deals and the possibility of more
Load More
We use cookies on this website. By using this site, you agree that we may store and access cookies on your device.
Find out more.
OK
Independent, data-driven daily news and analysis on pharma, biotech and medtech.
Sign up
Latest Reports
February 11, 2021
Evaluate Vantage Pharma, Biotech & Medtech 2020 in Review
December 10, 2020
Evaluate Vantage 2021 Preview
Editor's Picks
February 10, 2021
2020 wins top of the froths for biotech stocks
October 04, 2018
Biotech flotations remain in high demand
February 04, 2021
Glaxo’s growth problem
January 27, 2021
Go or no go? Oncology decisions ahead for the FDA
February 05, 2021
Pfizer reveals its PD-1 secret